TR-Dizin İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/9

Browse

Filters

2024 - 20252

Settings

Publication Index: search.filters.publicationIndex.ScopusSubject: search.filters.subject.Probiotic

Search Results

Now showing 1 - 2 of 2
  • Article
    Lactobacillus Rhamnosus GG Alleviates Bisphenol-A Induced Oxidative Stress in Serum
    (Marmara University, Faculty of Pharmacy, 2025) Şener, Göksel; Tunali-Akbay, Tugba; Dorucu, Dogancan; Ede-Pazarbasi, Seren; Dede, Pınar; Ede-Pazarbas, Seren
    The objective of this investigation was to identify changes in the serum oxidant-antioxidant balance of rats exposed to bisphenol A (BPA) and to investigate the impact of Lactobacillus rhamnosus GG (LGG) administration on those changes. Twenty-four rats (Wistar Albino, 250-300 grams, male) were divided into control, BPA, and BPA+LGG groups with an equal number of rats. BPA and LGG were applied to the rats in the relevant groups for six weeks, five days each week. Six weeks later, the blood samples were withdrawn and serum samples were prepared. Total oxidant and antioxidant status (TAS), glutathione, and lipid peroxidation determinations were determined in serum samples, and the oxidative stress index was calculated. BPA exposure decreased serum total antioxidant status and increased serum total oxidative status, oxidative stress index, and lipid peroxidation level compared to the control group. LGG administration improved the increased serum oxidative stress caused by BPA. Administration of LGG to BPA-treated rats reversed oxidative stress-induced changes. In conclusion, administration of Lactobacillus rhamnosus GG to rats for 30 consecutive days prevented oxidative stress in serum caused by bisphenol A.
  • Review
    Citation - WoS: 3
    Citation - Scopus: 4
    Oral Pharmabiotic Tablet Formulations
    (Marmara Univ, 2024) Kandur, Buse; Ugurlu, Timucin; Rayaman, Erkan; Ahbaz, Sevinc S.; Şahbaz, Sevinç
    Pharmabiotic is a unique and recent term used to describe formulations containing probiotics. Pharmabiotics are probiotics prepared in a pharmaceutical form used to treat diseases and disorders by making physicochemical changes in human health. Probiotics, prebiotics, and synbiotics are included in this scope, and enzobiotics, which are a rising class of supplements, should be evaluated in this context, as they are a subspecies of synbiotics. Pharmabiotics, unlike nutribiotics, do not necessarily contain live microorganisms. The best examples of these are paraprobiotics and postbiotics. Tablet formulations are suitable dosage forms for pharmabiotics due to their redundant superiority over other solid dosage forms. Tablets are frequently preferred because they can be produced at low cost, are easily transported, and modified, are suitable for large-scale production, and are more stable than other dosage forms. Considering the examples in the literature and the definition of pharmabiotic, several tablet formulations can be mentioned as pharmabiotics. They can be divided into conventional uncoated tablets, chewable tablets, and effervescent tablets. With recent studies, this classification has expanded, and buccal mucoadhesive tablets, ODTs (orally disintegrating tablets) and FDTs (fast disintegrating tablets), layered/multi-layered tablets, and tablets within tablets have also taken their place in the classification. This article focuses on oral tablet formulations that can be classified as pharmabiotics.